Advaxis Doses First Patient In CIN Clinical Trial
Advaxis said that the study is designed to assess the safety and efficacy of ADXS11-001, for the treatment of CIN grade 2/3 commonly known as cervical dysplasia. Reportedly,
BeOne Medicines is set to invest $300m in expanding its manufacturing and research operations at the Princeton West Innovation Campus in Hopewell, New Jersey, US.